{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-021573","form_type":"8-K","ticker":"CRMD","cik":"0001410098","company_name":"CorMedix Inc.","filed_at":"2024-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.100045+00:00","generated_at":"2026-06-04T22:57:49.261355+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CorMedix reports Q4 2023 net loss $14.8M; FDA approved DefenCath; launch April 2024","bullets":["Net loss Q4 2023 $14.8M ($0.26/sh) vs $8.2M ($0.20/sh) Q4 2022; operating expenses $15.7M.","Full year 2023 net loss $46.3M ($0.91/sh) vs $29.7M ($0.74/sh) in 2022.","FDA approved DefenCath Nov 15, 2023; commercial launch in inpatient setting planned April 15, 2024.","CMS TDAPA application under review; targeting July 1, 2024 outpatient launch.","Cash and short-term investments $76.0M at Dec 31, 2023; sufficient for at least 12 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-021573","json":"https://secwatch.observer/filing/0001213900-24-021573.json","markdown":"https://secwatch.observer/filing/0001213900-24-021573.md","text":"https://secwatch.observer/filing/0001213900-24-021573.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1410098/000121390024021573/0001213900-24-021573-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1410098/000121390024021573/ea0201559-8k_cormedix.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T22:57:49.261355+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ba8f8b460fe46401af3830bc0e98b8bef8559e8e","claim":"CorMedix Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income $46.3 million, or $0.91 per share, EPS $0.91 per share.","evidence_excerpt":"For the fourth quarter of 2023, CorMedix recorded a net loss of $14.8 million, or $0.26 per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390024021573/0001213900-24-021573-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Net income","value":"$46.3 million, or $0.91 per share"},{"label":"EPS","value":"$0.91 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"ba8f8b460fe46401af3830bc0e98b8bef8559e8e","claim":"CorMedix Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income $46.3 million, or $0.91 per share, EPS $0.91 per share.","evidence_excerpt":"For the year ended December 31, 2023, CorMedix recorded a net loss of $46.3 million, or $0.91 per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390024021573/0001213900-24-021573-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Net income","value":"$46.3 million, or $0.91 per share"},{"label":"EPS","value":"$0.91 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}